Cargando…
Trace element supplementation in hemodialysis patients: a randomized controlled trial
BACKGROUND: People with kidney failure are often deficient in zinc and selenium, but little is known about the optimal way to correct such deficiency. METHODS: We did a double-blind randomized trial evaluating the effects of zinc (Zn), selenium (Se) and vitamin E added to the standard oral renal vit...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4409771/ https://www.ncbi.nlm.nih.gov/pubmed/25884981 http://dx.doi.org/10.1186/s12882-015-0042-4 |
_version_ | 1782368234385702912 |
---|---|
author | Tonelli, Marcello Wiebe, Natasha Thompson, Stephanie Kinniburgh, David Klarenbach, Scott W Walsh, Michael Bello, Aminu K Faruque, Labib Field, Catherine Manns, Braden J Hemmelgarn, Brenda R |
author_facet | Tonelli, Marcello Wiebe, Natasha Thompson, Stephanie Kinniburgh, David Klarenbach, Scott W Walsh, Michael Bello, Aminu K Faruque, Labib Field, Catherine Manns, Braden J Hemmelgarn, Brenda R |
author_sort | Tonelli, Marcello |
collection | PubMed |
description | BACKGROUND: People with kidney failure are often deficient in zinc and selenium, but little is known about the optimal way to correct such deficiency. METHODS: We did a double-blind randomized trial evaluating the effects of zinc (Zn), selenium (Se) and vitamin E added to the standard oral renal vitamin supplement (B and C vitamins) among hemodialysis patients in Alberta, Canada. We evaluated the effect of two daily doses of the new supplement (medium dose: 50 mg Zn, 75 mcg Se, 250 IU vitamin E; low dose: 25 mg Zn, 50 mcg Se, 250 IU vitamin E) compared to the standard supplement on blood concentrations of Se and Zn at 90 days (primary outcome) and 180 days (secondary outcome) as well as safety outcomes. RESULTS: We enrolled 150 participants. The proportion of participants with low zinc status (blood level <815 ug/L) did not differ between the control group and the two intervention groups at 90 days (control 23.9% vs combined intervention groups 23.9%, P > 0.99) or 180 days (18.6% vs 28.2%, P = 0.24). The proportion with low selenium status (blood level <121 ug/L) was similar for controls and the combined intervention groups at 90 days (32.6 vs 19.6%, P = 0.09) and 180 days (34.9% vs 23.5%, P = 0.17). There were no significant differences in the risk of adverse events between the groups. CONCLUSIONS: Supplementation with low or medium doses of zinc and selenium did not correct low zinc or selenium status in hemodialysis patients. Future studies should consider higher doses of zinc (≥75 mg/d) and selenium (≥100 mcg/d) with the standard supplement. TRIAL REGISTRATION: Registered with ClinicalTrials.gov (NCT01473914) ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12882-015-0042-4) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4409771 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-44097712015-04-26 Trace element supplementation in hemodialysis patients: a randomized controlled trial Tonelli, Marcello Wiebe, Natasha Thompson, Stephanie Kinniburgh, David Klarenbach, Scott W Walsh, Michael Bello, Aminu K Faruque, Labib Field, Catherine Manns, Braden J Hemmelgarn, Brenda R BMC Nephrol Research Article BACKGROUND: People with kidney failure are often deficient in zinc and selenium, but little is known about the optimal way to correct such deficiency. METHODS: We did a double-blind randomized trial evaluating the effects of zinc (Zn), selenium (Se) and vitamin E added to the standard oral renal vitamin supplement (B and C vitamins) among hemodialysis patients in Alberta, Canada. We evaluated the effect of two daily doses of the new supplement (medium dose: 50 mg Zn, 75 mcg Se, 250 IU vitamin E; low dose: 25 mg Zn, 50 mcg Se, 250 IU vitamin E) compared to the standard supplement on blood concentrations of Se and Zn at 90 days (primary outcome) and 180 days (secondary outcome) as well as safety outcomes. RESULTS: We enrolled 150 participants. The proportion of participants with low zinc status (blood level <815 ug/L) did not differ between the control group and the two intervention groups at 90 days (control 23.9% vs combined intervention groups 23.9%, P > 0.99) or 180 days (18.6% vs 28.2%, P = 0.24). The proportion with low selenium status (blood level <121 ug/L) was similar for controls and the combined intervention groups at 90 days (32.6 vs 19.6%, P = 0.09) and 180 days (34.9% vs 23.5%, P = 0.17). There were no significant differences in the risk of adverse events between the groups. CONCLUSIONS: Supplementation with low or medium doses of zinc and selenium did not correct low zinc or selenium status in hemodialysis patients. Future studies should consider higher doses of zinc (≥75 mg/d) and selenium (≥100 mcg/d) with the standard supplement. TRIAL REGISTRATION: Registered with ClinicalTrials.gov (NCT01473914) ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12882-015-0042-4) contains supplementary material, which is available to authorized users. BioMed Central 2015-04-11 /pmc/articles/PMC4409771/ /pubmed/25884981 http://dx.doi.org/10.1186/s12882-015-0042-4 Text en © Tonelli et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Tonelli, Marcello Wiebe, Natasha Thompson, Stephanie Kinniburgh, David Klarenbach, Scott W Walsh, Michael Bello, Aminu K Faruque, Labib Field, Catherine Manns, Braden J Hemmelgarn, Brenda R Trace element supplementation in hemodialysis patients: a randomized controlled trial |
title | Trace element supplementation in hemodialysis patients: a randomized controlled trial |
title_full | Trace element supplementation in hemodialysis patients: a randomized controlled trial |
title_fullStr | Trace element supplementation in hemodialysis patients: a randomized controlled trial |
title_full_unstemmed | Trace element supplementation in hemodialysis patients: a randomized controlled trial |
title_short | Trace element supplementation in hemodialysis patients: a randomized controlled trial |
title_sort | trace element supplementation in hemodialysis patients: a randomized controlled trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4409771/ https://www.ncbi.nlm.nih.gov/pubmed/25884981 http://dx.doi.org/10.1186/s12882-015-0042-4 |
work_keys_str_mv | AT tonellimarcello traceelementsupplementationinhemodialysispatientsarandomizedcontrolledtrial AT wiebenatasha traceelementsupplementationinhemodialysispatientsarandomizedcontrolledtrial AT thompsonstephanie traceelementsupplementationinhemodialysispatientsarandomizedcontrolledtrial AT kinniburghdavid traceelementsupplementationinhemodialysispatientsarandomizedcontrolledtrial AT klarenbachscottw traceelementsupplementationinhemodialysispatientsarandomizedcontrolledtrial AT walshmichael traceelementsupplementationinhemodialysispatientsarandomizedcontrolledtrial AT belloaminuk traceelementsupplementationinhemodialysispatientsarandomizedcontrolledtrial AT faruquelabib traceelementsupplementationinhemodialysispatientsarandomizedcontrolledtrial AT fieldcatherine traceelementsupplementationinhemodialysispatientsarandomizedcontrolledtrial AT mannsbradenj traceelementsupplementationinhemodialysispatientsarandomizedcontrolledtrial AT hemmelgarnbrendar traceelementsupplementationinhemodialysispatientsarandomizedcontrolledtrial AT traceelementsupplementationinhemodialysispatientsarandomizedcontrolledtrial |